274:
221:
45:(CBT), along with timed notifications to keep the patient engaged and in treatment. Randomized controlled trials showed that the Rejoyn app was more effective at relieving depression symptoms compared to a "sham app", a
53:
in Boston, said that the app seems to pose minimal risks, and is an important step forward in unlocking the power of smartphones in treating psychiatric disorders.
258:
315:
41:, and gained FDA approval as a "medical device" on March 30th, 2024. The smartphone app helps patients with depression using exercises based on
50:
186:
251:
344:
364:
359:
88:
308:
244:
349:
42:
49:
app that required similar effort but was not intended to be helpful. Dr. John Torous, MD, MBI, a psychiatrist at the
334:
27:
354:
301:
113:
159:
38:
89:"FDA clears first digital treatment for depression, but experts caution that research is still early"
339:
273:
133:
285:
228:
145:
22:
is a prescription-only digital therapeutic smartphone app, it has been approved by the US
31:
328:
30:(MDD) in adults ages 22 and up. It is to be used in conjunction with a standard
281:
220:
46:
23:
187:"The FDA has approved the first app to help treat depression"
34:
medication, and with professional guidance and support.
289:
232:
309:
252:
8:
316:
302:
259:
245:
69:MBI for Masters of Biomedical Informatics.
79:
141:
131:
160:"FDA 510k Approval Notice for Rejoyn"
7:
270:
268:
217:
215:
51:Beth Israel Deaconess Medical Center
288:. You can help Knowledge (XXG) by
231:. You can help Knowledge (XXG) by
227:This mobile software article is a
39:Otsuka America Pharmaceutical Inc.
16:Digital therapeutic smartphone app
14:
120:. US Food and Drug Administration
272:
219:
114:"FDA Roundup: April 2nd, 2024"
1:
64:
43:cognitive behavioral therapy
185:Fadel, Leila (2024-04-04).
112:FDA Newsroom (2024-04-02).
381:
267:
214:
87:Cheng, Mira (2024-04-02).
28:Major Depressive Disorder
37:Rejoyn was developed by
345:Treatment of depression
284:-related article is a
365:Mobile software stubs
360:Otsuka Pharmaceutical
26:for the treatment of
166:. US FDA. 2024-03-30
350:Mobile applications
191:NPR Morning Edition
144:has generic name (
118:FDA Press Releases
297:
296:
240:
239:
372:
335:Psychiatry stubs
318:
311:
304:
276:
269:
261:
254:
247:
223:
216:
203:
202:
200:
198:
182:
176:
175:
173:
171:
156:
150:
149:
143:
139:
137:
129:
127:
125:
109:
103:
102:
100:
99:
84:
68:
380:
379:
375:
374:
373:
371:
370:
369:
355:Health software
325:
324:
323:
322:
266:
265:
212:
209:
207:
206:
196:
194:
184:
183:
179:
169:
167:
158:
157:
153:
140:
130:
123:
121:
111:
110:
106:
97:
95:
86:
85:
81:
76:
63:
59:
17:
12:
11:
5:
378:
376:
368:
367:
362:
357:
352:
347:
342:
337:
327:
326:
321:
320:
313:
306:
298:
295:
294:
277:
264:
263:
256:
249:
241:
238:
237:
224:
205:
204:
177:
151:
104:
78:
77:
75:
72:
71:
70:
58:
55:
32:antidepressant
15:
13:
10:
9:
6:
4:
3:
2:
377:
366:
363:
361:
358:
356:
353:
351:
348:
346:
343:
341:
338:
336:
333:
332:
330:
319:
314:
312:
307:
305:
300:
299:
293:
291:
287:
283:
278:
275:
271:
262:
257:
255:
250:
248:
243:
242:
236:
234:
230:
225:
222:
218:
213:
210:
192:
188:
181:
178:
165:
161:
155:
152:
147:
135:
119:
115:
108:
105:
94:
90:
83:
80:
73:
67:
66:
61:
60:
56:
54:
52:
48:
44:
40:
35:
33:
29:
25:
21:
290:expanding it
279:
233:expanding it
226:
211:
208:
195:. Retrieved
190:
180:
168:. Retrieved
163:
154:
142:|last1=
122:. Retrieved
117:
107:
96:. Retrieved
92:
82:
65:
36:
19:
18:
340:Psychiatry
329:Categories
282:psychiatry
98:2024-04-04
74:References
134:cite web
197:4 April
170:4 April
164:FDA.gov
124:4 April
47:placebo
20:Rejoyn
280:This
193:. NPR
57:Notes
286:stub
229:stub
199:2024
172:2024
146:help
126:2024
93:CNN
24:FDA
331::
189:.
162:.
138::
136:}}
132:{{
116:.
91:.
317:e
310:t
303:v
292:.
260:e
253:t
246:v
235:.
201:.
174:.
148:)
128:.
101:.
62:a
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
